Giant drug maker Anadys Pharmaceuticals Inc. has reported that its experimental medicine for hepatitis C, being called ANA598 for now, has managed to successfully reach all the important goals in the clinical trials mid-stage.

Based on immediate data released, the company has shared that a total of 56% of all the patients involved in the trial, who were given the experimental medicine in a combination treatment, had undetectable levels of the virus after 4 weeks of regular administration of treatment. In addition to the Anadys medicine, patients were also being given the standard drug for the condition, Ribavirin.

An independent Data Monitoring Committee has now recommended that the company should now try to increase the dose administered from 200 milligrams to 400 milligrams. It is expected that the firm would start the added dosage trials from January.

ANA598 has been facing some safety issues, and some patients dropped out of the study in its early stages, earlier this year, after they developed a rash.

In pre-market trading, shares of the company managed to rise by 9% to $3.20.